CYP2C19 and breast cancer: Their study demonstrated that elevated CYP2C19 leads to increased EET levels in a highly metastatic breast cancer cell line, LM6, and that using short hairpin RNA (shRNA) to silence CYP2C19 expression reduces EET levels and decreases the cell's metastatic potential.